✓ Medically reviewed by  ·  Last reviewed: May 2026

Morgan Ellis

Pharmacy Researcher · 8 years experience

Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.

Of the 30+ peptides actively used in longevity and recovery medicine in 2026, only one has reached FDA approval specifically for a mitochondrial disease. That peptide is SS-31 — also known as elamipretide, Bendavia, or by its trade name Elamipretide in the FDA-approved formulation for Barth syndrome (approved September 2025).

SS-31 is a four-amino-acid cell-penetrating peptide that targets the inner mitochondrial membrane — specifically the phospholipid cardiolipin — and stabilises the entire mitochondrial machinery that turns food into ATP. That may sound obscure, but the mitochondrial decline that drives heart failure, kidney disease, neurodegeneration, and much of general aging all share the same underlying chemistry: cardiolipin damage, cristae fragmentation, reduced ATP output, and elevated oxidative stress. SS-31 addresses all four in one molecule.

This guide is the technical-but-readable deep dive on what SS-31 actually is, how cardiolipin binding translates into clinical effects, the real research base (including the PROGRESS-HF, TAZPOWER, MMPOWER-3, and ReCLAIM trials), realistic dosing protocols, and how SS-31 fits into the broader mitochondrial-medicine landscape alongside NAD⁺ and other mitochondrial interventions.

SS-31 (Elamipretide): Mitochondrial Peptide, Dosage & The Honest Science (2026)

Last updated: April 17, 2026 · Reviewed by a licensed pharmacist (MedsBase Medical Team)

What Is SS-31? (Definition & Background)

SS-31 is a synthetic, cell-penetrating tetrapeptide — just four amino acids with the sequence D-arginine-2′6′-dimethyltyrosine-lysine-phenylalanine-amide. The unusual amino acids (D-arginine instead of L-arginine, and the modified tyrosine) give the molecule two critical properties: resistance to enzymatic degradation, and the ability to cross the plasma and mitochondrial membranes efficiently. It was developed by Hazel Szeto at Cornell in the early 2000s — hence “SS” for Szeto-Schiller — as part of a research program on cell-penetrating peptides that could selectively target mitochondria.

SS-31 carries several brand and code names. In preclinical literature it is typically called SS-31. In clinical development it became elamipretide (MTP-131). Stealth BioTherapeutics, the company that developed it through clinical trials, branded it Bendavia during cardiac-protection trials and Elamipretide in the formulation approved for Barth syndrome in September 2025.

That FDA approval — for a rare mitochondrial disease — was the first approval of any mitochondria-targeted peptide in history. It is a small-population indication (Barth syndrome is estimated to affect fewer than 1,000 patients in the US), but regulatory approval on the basis of cardiac improvement and exercise tolerance validates the core pharmacology. It also paves the way for the much larger cardiovascular and neurodegenerative indications currently in Phase 2 and 3 trials.

Outside these approved and investigational contexts, SS-31 is sold as a research compound for use in mitochondrial-biology research labs.

How Does SS-31 Work? (Mechanism & Science)

SS-31’s mechanism is one of the most precisely characterised in the peptide field.

1. Cardiolipin Binding

Cardiolipin is a unique phospholipid found almost exclusively on the inner mitochondrial membrane. It anchors the electron-transport-chain complexes (I through V) and helps form the cristae — the densely folded surface where ATP synthesis happens. When cardiolipin is damaged — by oxidation, aging, or inherited defects (as in Barth syndrome) — cristae fragment, complexes dissociate, ATP output falls, and oxidative stress rises.

SS-31 selectively binds cardiolipin. Once bound, the peptide stabilises the cardiolipin–protein complexes and protects the lipid from oxidative damage. This single binding event propagates benefits throughout the entire mitochondrial machinery.

2. Cristae Stabilisation

With cardiolipin stabilised, the cristae structure is preserved. Complex I, III, IV, and V activity all improve. Electron flow through the chain is more efficient, and the “leak” of electrons (which generate reactive oxygen species) is reduced.

3. Oxidative Stress Reduction

SS-31 reduces mitochondrial ROS generation in both healthy and damaged mitochondria. This is distinct from generic antioxidants — SS-31 stops the ROS at the source (the electron-transport chain) rather than quenching it after generation.

4. ATP Output Restoration

The functional result of all three upstream effects is measurable: improved mitochondrial oxygen flux, increased Complex I and IV activity, and higher ATP output. In failing human hearts — the most-studied clinical tissue — SS-31 treatment has shown 10–15% improvements in peak VO₂ after 4 weeks.

Key Uses & Applications

Barth Syndrome (FDA-Approved, September 2025)

A rare, X-linked genetic disorder of cardiolipin metabolism causing dilated cardiomyopathy, skeletal myopathy, and neutropenia. The FDA approval was based on trial data showing improved cardiac function and exercise tolerance (patients improved walking distance by an average of 96 meters per person).

Heart Failure with Reduced Ejection Fraction (In Development)

The PROGRESS-HF trial and predecessor studies have shown elamipretide improves peak VO₂ and mitochondrial function in HFrEF patients. Phase 3 development is ongoing.

Mitochondrial Myopathy (MMPOWER Trials)

The MMPOWER-3 trial tested SS-31 in primary mitochondrial myopathies. Mixed results overall but suggestive of benefit in specific genetic subgroups.

Age-Related Macular Degeneration (ReCLAIM Trial)

Dry AMD is another mitochondrial disease of the retina. The ReCLAIM trial tested elamipretide with interesting preliminary results; dry-AMD indications remain in active development.

General Longevity and Research Use

Off-label use in longevity clinics remains common. SS-31 pairs naturally with NAD⁺ support (the two address different but complementary aspects of mitochondrial decline) and with other longevity peptides.

Safety Profile, Side Effects & Dosage

SS-31 has been well-tolerated across a large clinical trial program.

Reported Side Effects

• Injection-site reactions — most common (redness, mild pain, occasional bruising).
• Headache — mild to moderate, typically transient.
• Mild diarrhea or nausea — uncommon.
• Fatigue — reported in a minority of users, usually resolves with continued dosing.

Dosage Reference Ranges

These are observational clinical ranges based on published trials; actual dosing should be set by a physician.

• Subcutaneous (research / longevity protocols): 0.1–2 mg/kg once daily, or 5–40 mg fixed dose daily.
• IV infusion (clinical): 0.01–0.25 mg/kg/h over 4 hours — used in trial protocols.
• Cycle length: 4–12 weeks typical for heart-failure research; continuous dosing in Barth syndrome.

Contraindications

Pregnancy and breastfeeding (insufficient data). No major known drug–drug interactions at studied doses. Anyone with active malignancy should discuss with their oncology team before using SS-31 in a longevity context.

What Does the Research Say?

Barth Syndrome — FDA-Approved Data

The pivotal open-label extension showed 8 patients improved walking distance by an average of 96 meters per person, with measurable cardiac stroke volume improvements. This data supported the September 2025 FDA approval.

Heart Failure — PROGRESS-HF and Predecessors

Trials in HFrEF patients have shown 10–15% improvements in peak VO₂ after 4 weeks of IV SS-31, along with improvements in mitochondrial function measured in cardiac biopsy tissue. Phase 3 development continues.

Preclinical Mitochondrial Research

Extensive. SS-31 has been tested in aging mouse models (with cardiac-function rescue in old mice), ischemia-reperfusion injury models, Alzheimer’s models, and Parkinson’s models. Preclinical effect sizes are substantial and mechanism-consistent.

Long-Term Safety Data

Multiple multi-year clinical trials provide strong long-term safety data by peptide-field standards. No major organ toxicity or adverse signals have emerged.

SS-31 vs NAD⁺ vs Other Mitochondrial Tools

Practical takeaway. SS-31 and NAD⁺ are the two headline mitochondrial peptide tools in 2026 — they address different, complementary problems. SS-31 fixes structural integrity of the mitochondrial machinery; NAD⁺ restores the cofactor that drives it. For serious mitochondrial disease or clinical heart-failure research, SS-31 has the trial data. For broader longevity and NAD⁺-depletion-driven aging, NAD⁺ precursors are cheaper, oral, and better-studied. Many protocols combine both.

How to Use SS-31 (Reconstitution, Storage, Administration)

Reconstitution

SS-31 ships as lyophilised powder in 5, 10, or 50 mg vials. For a 10 mg vial with 2 mL bacteriostatic water: 5 mg/mL — a 0.2 mL dose delivers 1 mg.

Storage

Reconstituted SS-31 is stable refrigerated (2–8 °C) for up to 28 days. Unreconstituted vials store indefinitely frozen. Protect from light.

Subcutaneous Administration

Standard technique with a 0.3–1 mL insulin syringe. Inject into abdomen, thigh, or upper arm. Rotate sites. Morning dosing is common — SS-31 does not typically affect sleep.

IV Administration

Clinical-trial IV administration is 0.01–0.25 mg/kg/h over 4 hours. This is not typical for research or longevity protocols; subcutaneous dosing is the more accessible route.

Cycle Structure

Continuous dosing is typical for Barth syndrome and for clinical-trial protocols. Longevity users often cycle 8–12 weeks on with 2–4 week breaks.

Frequently Asked Questions

What is SS-31 used for?

SS-31 (elamipretide) is FDA-approved for Barth syndrome (September 2025) and is in clinical development for heart failure, mitochondrial myopathy, and age-related macular degeneration. Off-label use in longevity and mitochondrial-support protocols is common under physician supervision.

Is SS-31 the same as elamipretide?

Yes. SS-31, elamipretide, Bendavia, and MTP-131 are all names for the same molecule. “Elamipretide” is the INN (international non-proprietary name) used in clinical development and in the FDA-approved product.

How quickly does SS-31 work?

In clinical trials, measurable improvements in peak VO₂ (heart failure) and exercise tolerance (Barth syndrome) appear within 4 weeks of consistent dosing. Subjective energy improvements are sometimes reported earlier but the reliable clinical signals are at 4+ weeks.

Is SS-31 safer than NAD⁺?

Both are well-tolerated. SS-31 has the stronger clinical-trial safety dataset because of its FDA trial program. NAD⁺ has the longer anecdotal safety record. For users without specific mitochondrial disease, NAD⁺ is more accessible and better-studied; for heart failure and diagnosed mitochondrial dysfunction, SS-31 has the more specific indication.

How much SS-31 should I use?

Research doses range from 0.1 to 2 mg/kg subcutaneous daily, or 5–40 mg fixed doses. Clinical IV dosing is 0.01–0.25 mg/kg/h over 4 hours. These are observational ranges; actual dosing should be set by a physician.

Can SS-31 help with heart failure?

Clinical trials have shown 10–15% improvements in peak VO₂ after 4 weeks of IV SS-31 in HFrEF patients. Phase 3 approval for heart failure has not yet occurred (as of April 2026). For patients with HFrEF, SS-31 access is primarily via clinical trials; for others, it remains investigational.

Can I stack SS-31 with other peptides?

Yes. Common pairings include SS-31 + NAD⁺ for comprehensive mitochondrial support (structural + cofactor), SS-31 + BPC-157 for recovery protocols, and SS-31 + CoQ10 or ubiquinol as a general mitochondrial-support triad.

Is SS-31 legal?

Elamipretide is FDA-approved as a prescription drug for Barth syndrome. Research-grade SS-31 is sold for laboratory research use in most jurisdictions. Off-label use in non-Barth indications requires prescription and physician supervision. Check local laws.

How long should an SS-31 cycle last?

Continuous dosing is typical for Barth syndrome and clinical trials. For research and longevity protocols, 8–12 weeks on with 2–4 week breaks is common, though the safety profile supports longer continuous use if medically indicated.

The Bottom Line — Is SS-31 Worth It?

SS-31 (elamipretide) is the first — and as of April 2026, only — FDA-approved mitochondria-targeted peptide. That approval, combined with a substantial Phase 2/3 clinical trial program and a precise mechanism (cardiolipin binding → cristae stabilisation → ATP output), makes SS-31 arguably the most clinically validated peptide in the mitochondrial-medicine space.

The limitations are practical. Research-grade SS-31 is relatively expensive compared to oral NAD⁺ precursors. Access to elamipretide (the FDA-approved formulation) is restricted to Barth syndrome patients. And the clinical outcomes data, while promising, is concentrated in narrow populations (Barth, HFrEF) rather than generalised to broader aging.

For patients with Barth syndrome, heart failure in clinical-trial settings, or diagnosed mitochondrial dysfunction, SS-31 is one of the most credible peptides in the entire field. For longevity users exploring mitochondrial support as one piece of a broader strategy, it has a strong mechanistic case and a favourable safety profile — just at a higher cost than oral precursors. Most practitioners combining mitochondrial tools use SS-31 (structural) alongside NAD⁺ (cofactor) for complementary coverage.

When sourcing high-purity research material, verified SS-31 at MedsBase ships with full documentation and pharmaceutical-grade purity across 5 mg, 10 mg, and 50 mg vial sizes. For the broader mitochondrial-biology picture, read our NAD⁺ coenzyme guide; for recovery-peptide pairings, see the best peptides for muscle recovery overview.

Related Guides

Written by

Sophie Chen

Pharmaceutical Content Researcher · 8 years experience

Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.